Become Affiliate

PepFlow

Download

The Mitochondrial Stabilizer

SS-31

SS-31 is elamipretide, a mitochondria-targeted tetrapeptide designed to associate with cardiolipin and support mitochondrial inner-membrane function.

Mitochondrial agingMitochondrial support
TierA
EvidenceStrong
SafetyWell-Studied
FDA statusApproved
Last reviewed October 25, 2026 26 citations How to read these labels

What is SS-31?

SS-31 is elamipretide, a mitochondria-targeted tetrapeptide designed to associate with cardiolipin and support mitochondrial inner-membrane function.[1][2][3]

As of September 19, 2025, FDA granted accelerated approval to elamipretide as Forzinity for Barth syndrome, making its regulatory status very different from most research-market mitochondrial peptides.[1][2][3]

That approval does not mean SS-31 is established for general anti-aging, athletic recovery, dry AMD, heart failure, or mitochondrial-wellness use.[1][2][3]

What SS-31 is investigated for

SS-31 evidence is grouped by practical use case and injectable and ophthalmic route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Barth syndrome

Injectable

80%Strong

Barth syndrome has the clearest clinical-development evidence for SS-31/elamipretide.[1][2][4]

Human evidence

Randomized and long-term extension data evaluate elamipretide in Barth syndrome.[1][2][4]

Animal / mechanistic evidence

Tafazzin knockdown mouse work supports the Barth mitochondrial mechanism.[3][5]

Primary mitochondrial myopathy and fatigue

Injectable

58%Emerging

Primary mitochondrial myopathy is human-studied but not as strong as the Barth syndrome evidence.[10][11]

Human evidence

MMPOWER-3 tested elamipretide in primary mitochondrial myopathy, with efficacy and safety results that require cautious interpretation.[10][11]

Animal / mechanistic evidence

Mechanistic reviews connect elamipretide to cardiolipin and mitochondrial bioenergetics.[10][11]

Mitochondrial function and cellular energy

Injectable

54%Emerging

Cellular-energy claims depend on mitochondrial disease biology, not broad wellness or anti-aging proof.[11][3][5]

Human evidence

Human mitochondrial-disease studies support the cellular-energy discussion indirectly through disease-specific endpoints.[10][11]

Animal / mechanistic evidence

Mechanism and tafazzin-model studies support mitochondrial morphology, mitophagy, and bioenergetic plausibility.[11][3][5]

Heart-failure mitochondrial function

Injectable

30%Limited

Heart-failure support is a separate preclinical mitochondrial-function signal.[26][11]

Human evidence

Human heart-failure outcome evidence is not established in the cited literature.[26][11]

Animal / mechanistic evidence

A dog model of advanced heart failure reported improved left-ventricular and mitochondrial function after chronic elamipretide therapy.[26][11]

Mitochondrial aging biology

Injectable

24%Limited

Mitochondrial aging biology is a plausible mechanism bucket, not evidence of human anti-aging benefit.[11][5]

Human evidence

Human anti-aging, longevity, or broad wellness outcomes are not established for SS-31/elamipretide.[10][11]

Animal / mechanistic evidence

Mechanistic reviews connect elamipretide to cardiolipin, mitochondrial bioenergetics, morphology, and stress adaptation, which explains the mitochondrial-aging rationale.[11][5]

Evidence snapshot

80%

Human evidence

Strong

FORZINITY labeling supports elamipretide for improving muscle strength in Barth syndrome under accelerated approval. Broader mitochondrial uses do not inherit that confidence.[1][2][3]

34%

Animal / preclinical

Limited

Cardiolipin and mitochondrial-membrane evidence directly support the Barth-syndrome rationale.[1][2][3]

80%

Mechanism support

Strong

Elamipretide is designed to interact with cardiolipin, a phospholipid important for mitochondrial inner-membrane structure and respiratory-chain function. The mechanism aims to stabilize mitochondrial energy machinery under stress.[1][2][3]

Forms & administration

Elamipretide has separate subcutaneous-injection and investigational eye-drop formulations. The eye solution and injectable vial differ in concentration, delivered amount and application schedule; each requires its own product-specific preparation and administration instructions.[12][9]

InjectableOphthalmic

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Subcutaneous protocols use 20-30 mg per day. A common starting dose is 20 mg.[12]

Frequency

Usually taken once daily.[12]

Timing Considerations

Morning is the usual timing.[12]

Cycle Length

Treatment commonly runs 52 weeks.[12]

What to expect

Weeks 4-12

Injectable elamipretide outcomes in mitochondrial-disease contexts center on muscle strength, fatigue, walking capacity, and daily function.[1][2][3][13][6]

Months

Injectable Barth-syndrome treatment may show gradual changes in disease-specific function, biomarkers, and confirmed strength outcomes.[1][2][3][13][6]

After stopping

Mitochondrial-disease benefits may lessen after injectable elamipretide ends if the underlying disease process remains active.[1][2][3][13][6]

Safety profile

SS-31 safety now includes Forzinity label data for Barth syndrome and a separate non-label mitochondrial-wellness context.[13][1]

Common side effects

Cautions

What we don't know

Barth-syndrome label data do not settle safety for non-label mitochondrial wellness use, different doses, or unsupervised compounded products.[13][1]

Who SS-31 is not for

Route-specific avoid and medical-review notes:

  • Use outside label without clinician oversight

    Use outside label without clinician oversight warrants medical review or avoidance for SS-31.[1][2][3]

  • Pregnancy or breastfeeding unless specifically supervised

    Pregnancy or breastfeeding unless specifically supervised warrants medical review or avoidance for SS-31.[1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Mitochondrial stacks

    CoQ10, NAD+ products, MOTS-c, or other mitochondrial supplements can blur fatigue, exercise, and symptom tracking; this is a mechanism-and-dose gap.[13][1]

  • Renal-stress drugs

    Nephrotoxic drugs or unstable renal medication regimens can make renal status and elamipretide tolerability harder to separate; this is a route-specific caution.[13][1]

  • Allergy-treatment overlap

    Antihistamines or corticosteroids can mask mild rash or hypersensitivity signals during early dosing; this is a route-specific caution.[13][1]

How it works

SS-31, now approved as elamipretide for Barth syndrome, is designed to interact with cardiolipin in the mitochondrial inner membrane. In practical terms, the mechanism aims to stabilize respiratory-chain structure and energy production under mitochondrial stress.[1][2][3]

Injectable delivery and disease context define the claim. The pathway is most meaningful in cardiolipin-related mitochondrial disease biology; it does not automatically translate into broad anti-aging, fatigue, athletic, or wellness benefits without indication-specific outcomes. The route and diagnosis narrow what the mitochondrial mechanism can reasonably imply.[1][2][3]

Research gaps & open questions

What the current literature has not yet settled about SS-31:

01

The required confirmatory trial still needs to show that improved knee-muscle strength translates into real benefits such as easier standing, walking, or daily activity for people with Barth syndrome.[1][2][3]

02

Separate trials need to show whether elamipretide helps people with dry age-related macular degeneration, primary mitochondrial muscle disease, heart failure, or other conditions; Barth-syndrome approval does not answer those questions.[1][2][3]

03

Studies need to establish safety and usefulness in people outside the approved rare-disease population, including the effects of long-term daily exposure.[1][2][3]

Common questions

Is SS-31 FDA-approved?

Yes. FDA granted accelerated approval to FORZINITY elamipretide for Barth syndrome; that does not approve general mitochondrial wellness or anti-aging use.[6][7][1]

Is SS-31 approved for anti-aging?

No. SS-31 is not FDA-approved for anti-aging; the U.S. approval and human outcomes are disease-specific for Barth syndrome.[6][7][1]

Is elamipretide the same as SS-31?

Yes. Elamipretide is the drug name associated with SS-31; approved use is indication-specific, not a blanket mitochondrial wellness claim.[6][7][1]

Myths & misconceptions

Myth

FDA approval means SS-31 is proven for all mitochondrial goals.

Reality

Approval is for a specific disease setting and cannot be generalized automatically.[1][2][3]

Myth

Mitochondrial support equals longevity benefit.

Reality

Mitochondrial mechanism is not the same as proven lifespan or anti-aging outcome.[1][2][3]

History & discovery

SS-31, later developed as elamipretide, began as a mitochondria-targeted peptide aimed at cardiolipin and inner-membrane stress biology. Barth syndrome eventually became the clearest clinical path. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[1][2][3][13]

Clinical trials and long-term extension data tied elamipretide to Barth syndrome, a cardiolipin-related mitochondrial disease. That moved SS-31 from broad mitochondrial interest into a defined indication.[1][2][3][13]

FDA accelerated approval for FORZINITY made the history disease-specific: approved elamipretide is a Barth syndrome therapy, not a blanket mitochondrial wellness or anti-aging product.[1][2][3][13]

Published research26 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Build consistency around your healthy-aging goals.

Use PepFlow to record your SS-31 protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00